ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML)
Open Access
- 1 May 2005
- journal article
- guideline
- Published by Elsevier in Annals of Oncology
- Vol. 16 (suppl_1) , i52-i53
- https://doi.org/10.1093/annonc/mdi807
Abstract
1Invited author, Dept. Hematology, University Hospital, Uppsala, Sweden; 2Assigned task force member, Elisabeth Krankenhaus GmbH, Abt. Onkologie/Hämatologie, Röntgenstrasse 10, 45 661 Recklinghausen, Germany; 3Assigned task force member, Div. of Oncology, University Hospital, Rämistr. 100, CH-8091 Zürich, SwitzerlandKeywords
This publication has 4 references indexed in Scilit:
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project GroupJNCI Journal of the National Cancer Institute, 1998
- Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patientsBlood, 1990
- Prognostic discrimination in "good-risk" chronic granulocytic leukemiaBlood, 1984